Hypersensitivity: Clinical Trials

9,615 trials for Hypersensitivity, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6323 completed, 1066 unknown, 751 recruiting, 523 terminated. 2345 Not applicable, 1777 Phase 2, 1470 Phase 3, 953 Phase 1, 893 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable2345Completed 1417, Unknown 364, Recruiting 200, Not yet recruiting 117, Terminated 99, Withdrawn 72, Active not recruiting 48, Enrolling by invitation 20, Suspended 8
Phase 21777Completed 1222, Terminated 162, Recruiting 116, Unknown 90, Withdrawn 81, Active not recruiting 59, Not yet recruiting 39, Enrolling by invitation 8
Phase 31470Completed 1113, Recruiting 78, Unknown 78, Terminated 68, Withdrawn 52, Active not recruiting 45, Not yet recruiting 27, Enrolling by invitation 8, Suspended 1
Phase 1953Completed 700, Terminated 79, Recruiting 54, Unknown 42, Withdrawn 33, Not yet recruiting 22, Active not recruiting 20, Enrolling by invitation 2, Suspended 1
Phase 4893Completed 627, Unknown 93, Terminated 63, Recruiting 38, Withdrawn 26, Not yet recruiting 23, Active not recruiting 21, Enrolling by invitation 2
Early Phase 170Completed 43, Unknown 8, Terminated 7, Active not recruiting 4, Enrolling by invitation 4, Recruiting 2, Not yet recruiting 1, Withdrawn 1

Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients
Skin Cleanser Combination No.1 - Atopic Dermatitis
Phase 4Not yet recruitingBoston Children's Hospital1002031-01-012026-03-10
Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis
Ivermectin Pill - Atopic Dermatitis
Phase 2WithdrawnStanford University2030-12-012024-12-02
Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis
Site specific standard of care comparison - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
WithdrawnMassachusetts General Hospital2030-01-012026-01-16
EFFECT OF AYURVEDA TREATMENT IN ALLERGIC RHINITIS
AYURVEDA treatment protocol, Control(Citrizine 10mg) - Allergic Rhinitis (AR)
Not applicableNot yet recruitingAmrita Vishwa Vidyapeetham1042028-06-302026-06-04
Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis
EC-18, Placebo EC-18 - Atopic Dermatitis
Phase 2Not yet recruitingEnzychem Lifesciences Corporation1502027-05-012026-08-28
Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age
Abrocitinib, Placebo - Atopic Dermatitis
Phase 3Not yet recruitingPfizer902027-05-012026-09-16
Rapid Escalation Oral Immunotherapy to Achieve Remission in Children With Cashew Allergy
cashew oral immunotherapy - Food Allergy in Children
Not applicableNot yet recruitingMurdoch Childrens Research Institute252027-05-012026-11-03
Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia)
linvemastat, Placebo - Asthma (Diagnosis), Pulmonary Function
Phase 2Not yet recruitingForesee Pharmaceuticals Co., Ltd.1352027-03-012026-07-20
UNC Cashew Sublingual Immunotherapy
Cashew sublingual immunotherapy, Placebo sublingual immunotherapy - Cashew Nut Allergy, Tree Nut Allergies
Phase 2Not yet recruitingUniversity of North Carolina, Chapel Hill452027-03-012026-10-20
Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy
HDM sublingual Immunotherapy, Placebo - Asthma, Allergy
Phase 2WithdrawnBoston Children's Hospital2027-02-012024-11-26
Prevent Wheeze Trial
Dexamethasone 0.6 mg/kilogram body weight single dose, Placebo - Lower Respiratory Tract Infection (LRTI), Recurrent Wheezing
Phase 4Not yet recruitingNorwegian University of Science and Technology4862027-02-012026-10-05
Changes in Symptom and Quality of Life in Patients With Uncontrolled Asthma Treated With Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI)
Budesonide/Glycopyrronium/Formoterol fumarate metered dose inhaler - Asthma, Uncontrolled Asthma
Not yet recruitingAstraZeneca2002027-01-292026-11-12
Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome)
Benralizumab 30 MG/ML [Fasenra], Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride - DRESS Syndrome
Phase 2Not yet recruitingUniversity Hospital, Lille962027-01-062026-05-15
Educational Needs of Patients With Severe Asthma on Targeted Immunotherapies
Initial assesment interwiew, Intake Interview with the Patient - Severe Asthma
Not yet recruitingUniversity Hospital, Angers202027-01-042026-10-02
GOAt Milk Formula-based Ladder Versus Cow's Milk Ladder
oral food challenge (OFC) - Food Allergy, Cow's Milk Protein Allergy
Not applicableNot yet recruitingMedical University of Warsaw922027-01-022026-08-31
Educational Eczema Video Intervention
in-clinic video intervention, at home video intervention - Eczema
Not applicableWithdrawnBoston Children's Hospital2027-01-012026-10-19
Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy
Partially Hydrolyzed Whey Protein Formula, Intact Cow's Milk Protein Formula - Mild Allergic Symptoms in Infants, Infant Feeding Intolerance
Not applicableNot yet recruitingRuijin Hospital1602027-01-012026-08-18
Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA )
Slow Release DHEA, Placebo - Asthma
Phase 2Not yet recruitingIndiana University302027-01-012026-02-27
Nebulized Ketamine for Severe Asthma Attacks in Children
Ketamine (1 mg/kg), Placebo - Asthma Acute, Exacerbation of Allergic Asthma
Phase 2Not yet recruitingSultan Qaboos University602027-01-012026-07-27
Immunotherapy for Curing Toddlers With Severe Food Allergy - a Paradigm Shift From Passive to Active Treatment With Multi-allergen Oral Immunotherapy
OIT multiallergen powder, Placebo powder - Food Allergy in Children
Not applicableNot yet recruitingOdense University Hospital802027-01-012026-10-27

Showing 20 of 9615. Sign in to see all of them.

Narrower conditions

Asthma (4474)  ·  Dermatitis, Atopic (1522)  ·  Rhinitis, Allergic (682)  ·  Pulmonary Disease, Chronic Obstructive (456)  ·  Rhinitis, Allergic, Seasonal (384)  ·  Eczema (370)  ·  Food Hypersensitivity (360)  ·  Sarcoidosis (249)  ·  Eosinophilic Esophagitis (234)  ·  Conjunctivitis, Allergic (197)  ·  Chronic Urticaria (194)  ·  Rhinitis, Allergic, Perennial (178)  ·  Angioedemas, Hereditary (169)  ·  Peanut Hypersensitivity (165)

Broader conditions

Immune System Diseases (9550)  ·  Hypersensitivity, Immediate (8497)  ·  Respiratory Tract Diseases (5783)  ·  Respiratory Hypersensitivity (5568)  ·  Lung Diseases (4577)  ·  Bronchial Diseases (4542)  ·  Lung Diseases, Obstructive (4466)  ·  Skin and Connective Tissue Diseases (2299)  ·  Skin Diseases (2206)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1874)  ·  Genetic Diseases, Inborn (1822)  ·  Pathological Conditions, Signs and Symptoms (1652)  ·  Skin Diseases, Eczematous (1601)  ·  Dermatitis (1571)

Interventions

Fluticasone (244)  ·  Budesonide (203)  ·  montelukast (179)  ·  Albuterol (162)  ·  Omalizumab (159)  ·  dupilumab (159)  ·  Mometasone Furoate (107)  ·  Formoterol Fumarate (105)  ·  Beclomethasone (88)  ·  Fluticasone-Salmeterol Drug Combination (87)  ·  Salmeterol Xinafoate (81)  ·  Blood Specimen Collection (80)  ·  Budesonide, Formoterol Fumarate Drug Combination (80)  ·  Sodium Chloride (66)  ·  benralizumab (58)

Sponsors

AstraZeneca (347)  ·  GlaxoSmithKline (346)  ·  Novartis Pharmaceuticals (157)  ·  Organon and Co (152)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (115)  ·  Sanofi (99)  ·  Pfizer (89)  ·  National Heart, Lung, and Blood Institute (NHLBI) (82)  ·  Assistance Publique - Hôpitaux de Paris (77)  ·  Boehringer Ingelheim (71)  ·  Chiesi Farmaceutici S.p.A. (62)  ·  Johns Hopkins University (60)  ·  Imperial College London (58)  ·  Regeneron Pharmaceuticals (58)  ·  University of North Carolina, Chapel Hill (56)

Countries

United States (3407)  ·  Germany (942)  ·  Canada (921)  ·  United Kingdom (891)  ·  France (720)  ·  China (609)  ·  Poland (542)  ·  Spain (533)  ·  Italy (467)  ·  Netherlands (360)  ·  Japan (339)  ·  Australia (338)  ·  South Korea (287)  ·  Belgium (275)  ·  Hungary (269)

Results publications

PMID 36472162, PMID 36326435, PMID 27881132, PMID 35636689, PMID 39393433, PMID 39588375, PMID 31319851, PMID 33006765, PMID 33305842, PMID 33826132, PMID 34389504, PMID 29400693, PMID 32926419, PMID 35691614, PMID 42162528, PMID 33217063, PMID 34406619, PMID 36255569, PMID 36723913, PMID 38127464, PMID 38814736, PMID 38896380, PMID 40993471, PMID 19001265, PMID 26704701, PMID 30954640, PMID 33165005, PMID 34037993, PMID 36408587, PMID 36853224, PMID 39104653, PMID 40028832, PMID 18331513, PMID 20818886, PMID 22329608, PMID 23312695, PMID 23878046, PMID 24184147, PMID 24712435, PMID 28065396, PMID 29174062, PMID 29536781, PMID 29656145, PMID 31066001, PMID 32180164, PMID 33453450, PMID 34098955, PMID 34142350, PMID 35061234, PMID 35342978

NIH funding

2018 (64), 2023 (53), 2015 (43), 2019 (43), 2017 (42), 2014 (41), 2016 (41), 2025 (34), 2009 (33), 2008 (18), 2004 (9), U10HL098115 (8), U10HL074212 (6), 2005 (5), P01HL107202 (5)